These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35421583)

  • 21. Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease.
    López IC; Aroca FG; Bernal MDF; Mompeán JAL; Bernal ÁB; Martínez AMH; Barba EM; Velasco JAN; Paricio PP
    Obes Surg; 2017 Sep; 27(9):2347-2353. PubMed ID: 28229316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
    Noureddin M; Truong E; Gornbein JA; Saouaf R; Guindi M; Todo T; Noureddin N; Yang JD; Harrison SA; Alkhouri N
    J Hepatol; 2022 Apr; 76(4):781-787. PubMed ID: 34798176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Compare the Combined Diagnostic Accuracy of Transient Elastography and Visual Liver Score in Assessing Non-Alcoholic Fatty Liver Disease (NAFLD) and Compare it with Liver Biopsy in Morbidly Obese Patients Undergoing Bariatric Surgery: An Observational Study.
    Sharma D; Anand G; Meena S; Bhardwaj V
    Obes Surg; 2024 Apr; 34(4):1247-1256. PubMed ID: 38411879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis.
    Angelini G; Panunzi S; Castagneto-Gissey L; Pellicanò F; De Gaetano A; Pompili M; Riccardi L; Garcovich M; Raffaelli M; Ciccoritti L; Verrastro O; Russo MF; Vecchio FM; Casella G; Casella-Mariolo J; Papa L; Marini PL; Rubino F; le Roux CW; Bornstein S; Mingrone G
    Gut; 2023 Feb; 72(2):392-403. PubMed ID: 35820779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease.
    Yang M; Jiang L; Wang Y; Li X; Zou Z; Han T; Nan Y; Lu F; Zhao J
    J Gastrointestin Liver Dis; 2019 Sep; 28(3):289-296. PubMed ID: 31517325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis.
    Okanoue T; Ebise H; Kai T; Mizuno M; Shima T; Ichihara J; Aoki M
    J Gastroenterol; 2018 Jan; 53(1):129-139. PubMed ID: 28589339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FICK-3 Score Combining Fibrosis-4, Insulin Resistance and Cytokeratin-18 in Predicting Non-alcoholic Steatohepatitis in NAFLD Egyptian Patients.
    Mohammed MA; Omar NM; Mohammed SA; Amin AM; Gad DF
    Pak J Biol Sci; 2019 Jan; 22(10):457-466. PubMed ID: 31930835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients.
    Francque SM; Verrijken A; Mertens I; Hubens G; Van Marck E; Pelckmans P; Michielsen P; Van Gaal L
    Clin Gastroenterol Hepatol; 2012 Oct; 10(10):1162-8; quiz e87. PubMed ID: 22796457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performance of noninvasive scores for the diagnosis of advanced liver fibrosis in morbidly obese with nonalcoholic fatty liver disease.
    de Carli MA; de Carli LA; Correa MB; Junqueira G; Tovo CV; Coral GP
    Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):420-425. PubMed ID: 31464779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD).
    Brandman D; Boyle M; McPherson S; Van Natta ML; Sanyal AJ; Kowdley K; Neuschwander-Tetri B; Chalasani N; Abdelmalek MF; Terrault NA; McCullough A; Bettencourt R; Caussy C; Kleiner DE; Behling C; Tonascia J; Anstee QM; Loomba R;
    Aliment Pharmacol Ther; 2022 Jun; 55(11):1441-1451. PubMed ID: 35302256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Derivation and validation of a scoring system for predicting nonalcoholic steatohepatitis in Taiwanese patients with severe obesity.
    Tai CM; Yu ML; Tu HP; Huang CK; Hwang JC; Chuang WL
    Surg Obes Relat Dis; 2017 Apr; 13(4):686-692. PubMed ID: 28089433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
    Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
    J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study.
    Younes R; Rosso C; Petta S; Cucco M; Marietti M; Caviglia GP; Ciancio A; Abate ML; Cammà C; Smedile A; Craxì A; Saracco GM; Bugianesi E
    Liver Int; 2018 Apr; 38(4):715-723. PubMed ID: 29028281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
    Corey KE; Pitts R; Lai M; Loureiro J; Masia R; Osganian SA; Gustafson JL; Hutter MM; Gee DW; Meireles OR; Witkowski ER; Richards SM; Jacob J; Finkel N; Ngo D; Wang TJ; Gerszten RE; Ukomadu C; Jennings LL
    J Hepatol; 2022 Jan; 76(1):25-33. PubMed ID: 34600973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiparametric US for Identifying Patients with High-Risk NASH: A Derivation and Validation Study.
    Sugimoto K; Lee DH; Lee JY; Yu SJ; Moriyasu F; Sakamaki K; Oshiro H; Takahashi H; Kakegawa T; Tomita Y; Abe M; Yoshimasu Y; Takeuchi H; Choi BI; Itoi T
    Radiology; 2021 Dec; 301(3):625-634. PubMed ID: 34519576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH.
    Boursier J; Anty R; Vonghia L; Moal V; Vanwolleghem T; Canivet CM; Michalak S; Bonnafous S; Michielsen P; Oberti F; Iannelli A; Van Gaal L; Patouraux S; Blanchet O; Verrijken A; Gual P; Rousselet MC; Driessen A; Hunault G; Bertrais S; Tran A; Calès P; Francque S
    Aliment Pharmacol Ther; 2018 May; 47(10):1387-1396. PubMed ID: 29577364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PERFORMACE OF TRIGLYCERIDE-GLUCOSE INDEX ON DIAGNOSIS AND STAGING OF NAFLD IN OBESE PATIENTS.
    Smiderle CA; Coral GP; DE Carli LA; Mattos AA; Mattos AZ; Tovo CV
    Arq Gastroenterol; 2021; 58(2):139-144. PubMed ID: 34231659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.